Robert-Rössle-Strasse 10
Berlin 13125
Germany
49 30 94 10 84 138
https://www.ezag.com
Settore/i:
Settore:
Impiegati a tempo pieno: 866
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Andreas Eckert Ph.D. | Chairman of Exec. Board & CEO | 478,03k | N/D | 1960 |
Dr. Harald Hasselmann | Head of Radiation Therapy Segment & Member of the Exec. Board | 249,73k | N/D | 1967 |
Dr. Lutz Helmke | Member of Exec. Board | 253,26k | N/D | 1961 |
Dr. Gunnar Mann | Head of Intragroup Services | N/D | N/D | 1967 |
Mr. Franklin B. Yeager | Pres of Eckert & Ziegler Isotope Products Inc. | N/D | N/D | N/D |
Mr. Joseph Hathcock | VP of Eckert & Ziegler Isotope Products Inc | N/D | N/D | N/D |
Ivan Simmer | Managing Director of Eckert & Ziegler Cesio s.r.o. | N/D | N/D | N/D |
Ms. Claudia Goulart | MD - Eckert & Ziegler Brasil Participacoes, Comericial & Logistica Ltda. | N/D | N/D | N/D |
Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, manufactures and sells isotope technology components for medical, scientific, and industrial applications worldwide. It operates through two segments, Medical and Isotope Products. The Medical segment offers small radioactive implants for the treatment of prostate cancer seeds; and eye application based on ruthenium-106 or iodine-125 for treating uveal melanoma. This segment provides radiopharmaceuticals, laboratory equipment, hot cells, and services for radiopharmaceuticals, as well as tumor irradiation equipment, eye applicators, and prostate implants. The Isotope Products segment manufactures and sells radiation sources for imaging, measurement technology, quality assurance, and environmental monitoring. This segment offers flood source, irradiation device, medical imaging source, ophthalmic applicator, quality control device, x-ray therapy device, and radiosynthesis system. The company was founded in 1992 and is headquartered in Berlin, Germany.
L'ISS Governance QualityScore di Eckert & Ziegler Strahlen- und Medizintechnik AG al 1 maggio 2022 è 10. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 10; diritti degli azionisti: 1; retribuzione: 9.